

DiaSorin gets EUA for Liaison SARS-CoV-2 Ag

April 1, 2021—[DiaSorin](#) received emergency use authorization from the FDA for its Liaison SARS-CoV-2 Ag.

The test uses chemiluminescence immunoassay technology to determine the presence of SARS-CoV-2 nucleocapsid protein antigen in anterior nasal dry swabs and nasopharyngeal swabs, eluted in universal transport medium, and is used to assist in the diagnosis of acute COVID-19 infection through qualitative detection of the virus.

In clinical studies the test showed a 97 percent sensitivity within 10 days post onset of symptoms and a 100 percent specificity on anterior nasal swabs, and a 96.1 percent sensitivity and a 99.3 percent specificity on nasopharyngeal swabs.

The Liaison SARS-CoV-2 Ag runs on the company's Liaison XL platform.